| Patient | Christopher Reeve |
|---|---|
| Date of birth | 1975-09-25 |
| Identifiers | MRN HR-ML024-SYN; SSN (made up) 000-24-7765 |
| Document date | 2026-11-01 |
| Author | Teresa Galloway, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for chronic C2 tetraplegia on a ventilator, some weeks after a diaphragm pacing system was implanted: autonomic dysreflexia plan, skin, bladder, bowel, respiratory care, bone and cardiometabolic health, mood, and care team needs. Concerns: He wants to spend longer each day breathing with the pacer instead of the ventilator; He wants to keep working and traveling without a hospital stay, and to keep his skin healthy; He wants to keep building strength and sensation through his exercise program. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sennosides 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 2026-04-13 | active | S |
| Nitroglycerin 2% ointment, one inch to the skin of the chest only if systolic blood pressure stays at 150 mmHg or higher after the first steps of the autonomic dysreflexia plan; wipe off when pressure falls | As needed for autonomic dysreflexia, under the written plan | Topical route | 2026-04-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets up to three times a day as needed for neck and shoulder aching | Two tablets up to three times a day as needed | Oral route | 2026-04-13 | active | S |
| Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-04-27 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Dual-energy X-ray absorptiometry (DXA) of the hip, with distal femur and proximal tibia views | 2026-04-27 to 2026-04-27 | completed | S |
| Ultrasound of both kidneys and the bladder | 2026-04-27 to 2026-04-27 | completed | S |
| Advance care planning conversation, about 30 minutes | 2026-09-14 to 2026-09-14 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-09-14 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-09-14 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-09-14 | Respiratory syncytial virus vaccine (RSVPreF3, adjuvanted) | completed | S |
| 2026-09-14 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 2026-10-26 | Influenza vaccine, inactivated, this season | completed | S |
| 2026-10-26 | COVID-19 vaccine, mRNA, this season | completed | S |
| 2026-10-26 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| May 27, 1995 | Fractures of the first and second cervical vertebrae with spinal cord injury in a riding fall; unable to breathe on his own afterwards | D (CLM-0003) |
| 1999 | Activity-based recovery program (electrically stimulated cycling and pool therapy) begun about five years after the injury; by his physicians' report, improvement from ASIA grade A to C, reversal of osteoporosis, less spasticity, and far fewer infections | D (CLM-0007, CLM-0008) |
| 2003 | Diaphragm pacing system implanted laparoscopically in Cleveland; able to breathe more than two hours off the ventilator afterwards | D (CLM-0009) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He wants to spend longer each day breathing with the pacer instead of the ventilator | active | S |
| He wants to keep working and traveling without a hospital stay, and to keep his skin healthy | active | S |
| He wants to keep building strength and sensation through his exercise program | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 6.8 on 2026-10-26; Hemoglobin [Mass/volume] in Blood 13.4 on 2026-10-26; Sodium [Moles/volume] in Serum or Plasma 138 on 2026-10-26; Potassium [Moles/volume] in Serum or Plasma 4.1 on 2026-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.49 on 2026-10-26; Cystatin C [Mass/volume] in Serum or Plasma 0.91 on 2026-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Cystatin C-based formula/1.73 sq M 92 on 2026-10-26; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-10-26; Calcium [Mass/volume] in Serum or Plasma 9 on 2026-04-13; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2026-06-22; Parathyrin.intact [Mass/volume] in Serum or Plasma 52 on 2026-04-13; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-04-13; Cholesterol [Mass/volume] in Serum or Plasma 172 on 2026-04-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 104 on 2026-04-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 34 on 2026-04-13; Triglyceride [Mass/volume] in Serum or Plasma 170 on 2026-04-13; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-10-26; Braden scale total score 12 on 2026-10-26; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 2026-10-26; DXA Femur [T-score] Bone density -1.6 on 2026-04-27; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-14 [S]
Strengths and supports: Supports: his family, his nursing team, colleagues in his advocacy work, and a strong sense of purpose in his work and research goals [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic incomplete C2 tetraplegia (ASIA grade C) from a traumatic spinal cord injury in a riding fall eight years ago, with partial late recovery of sensation and movement; uses a power wheelchair and has 24-hour nursing support; at risk of autonomic dysreflexia; synthetic modern episode linked to his documented injury and his physicians' published report | active | confirmed | G82.52 | S — Synthetic modern coding of the documented injury and the published ASIA grade. |
| Chronic ventilatory failure from the high cervical injury: dependent on a ventilator through a tracheostomy, with a diaphragm pacing system implanted some weeks ago and a conditioning program to lengthen time on the pacer; synthetic modern episode linked to his documented ventilator use and pacing | active | confirmed | Z99.11 | S — Synthetic modern coding of the documented ventilator dependence. |
| Neurogenic bladder after spinal cord injury, managed with an indwelling catheter | active | confirmed | N31.9 | S — Synthetic; expected with this level of injury. No public source describes his bladder care. |
| Neurogenic bowel after spinal cord injury, managed with a daily morning bowel program | active | confirmed | K59.2 | S — Synthetic; expected with this level of injury. No public source describes his bowel care. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-13 | Leukocytes [#/volume] in Blood by Automated count | 7.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-13 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-04-13 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.48 | mg/dL | 0.74-1.35 mg/dL | Low | S |
| 2026-04-13 | Cystatin C [Mass/volume] in Serum or Plasma | 0.92 | mg/L | 0.53-0.95 mg/L | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Cystatin C-based formula/1.73 sq M | 90 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-13 | Albumin [Mass/volume] in Serum or Plasma | 3.8 | g/dL | 3.5-5.2 g/dL | Normal | S |
| 2026-04-13 | Calcium [Mass/volume] in Serum or Plasma | 9 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-04-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-04-13 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 52 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-04-13 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-04-13 | Cholesterol [Mass/volume] in Serum or Plasma | 172 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 104 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-04-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 34 | mg/dL | >=40 mg/dL | Low | S |
| 2026-04-13 | Triglyceride [Mass/volume] in Serum or Plasma | 170 | mg/dL | <=149 mg/dL | High | S |
| 2026-04-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-04-13 | Braden scale total score | 11 | {score} | S | ||
| 2026-04-13 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S | ||
| 2026-04-27 | DXA Femur [T-score] Bone density | -1.6 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2026-04-27 | Braden scale total score | 11 | {score} | S | ||
| 2026-06-22 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-06-22 | Braden scale total score | 11 | {score} | S | ||
| 2026-06-22 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 2026-08-24 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-24 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-24 | Creatinine [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.74-1.35 mg/dL | Low | S |
| 2026-08-24 | Cystatin C [Mass/volume] in Serum or Plasma | 0.9 | mg/L | 0.53-0.95 mg/L | Normal | S |
| 2026-08-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Cystatin C-based formula/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-24 | Braden scale total score | 12 | {score} | S | ||
| 2026-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-10-26 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.49 | mg/dL | 0.74-1.35 mg/dL | Low | S |
| 2026-10-26 | Cystatin C [Mass/volume] in Serum or Plasma | 0.91 | mg/L | 0.53-0.95 mg/L | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Cystatin C-based formula/1.73 sq M | 92 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-26 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5.2 g/dL | Normal | S |
| 2026-10-26 | Braden scale total score | 12 | {score} | S | ||
| 2026-10-26 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-09-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-13 | Body height | 193 | cm | S |
| 2026-04-13 | Body weight | 82 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 62 | /min | S |
| 2026-04-13 | Respiratory rate | 12 | /min | S |
| 2026-04-13 | Body temperature | 36.3 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-04-27 | Body height | 193 | cm | S |
| 2026-04-27 | Body weight | 82.2 | kg | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-04-27 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-04-27 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-04-27 | Heart rate | 60 | /min | S |
| 2026-04-27 | Respiratory rate | 12 | /min | S |
| 2026-04-27 | Body temperature | 36.4 | Cel | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-06-22 | Body height | 193 | cm | S |
| 2026-06-22 | Body weight | 82.6 | kg | S |
| 2026-06-22 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 2026-06-22 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-06-22 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-06-22 | Heart rate | 64 | /min | S |
| 2026-06-22 | Respiratory rate | 12 | /min | S |
| 2026-06-22 | Body temperature | 36.5 | Cel | S |
| 2026-06-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-24 | Body height | 193 | cm | S |
| 2026-08-24 | Body weight | 82.8 | kg | S |
| 2026-08-24 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 2026-08-24 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-08-24 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-08-24 | Heart rate | 62 | /min | S |
| 2026-08-24 | Respiratory rate | 12 | /min | S |
| 2026-08-24 | Body temperature | 36.4 | Cel | S |
| 2026-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-10-26 | Body height | 193 | cm | S |
| 2026-10-26 | Body weight | 83 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 60 | /min | S |
| 2026-10-26 | Respiratory rate | 12 | /min | S |
| 2026-10-26 | Body temperature | 36.3 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-14 | Body height | 193 | cm | S |
| 2026-09-14 | Body weight | 82.9 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 62 | /min | S |
| 2026-09-14 | Respiratory rate | 12 | /min | S |
| 2026-09-14 | Body temperature | 36.4 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-04-13 | Establishing primary care for chronic C2 tetraplegia on a ventilator, some weeks after a diaphragm pacing system was implanted: autonomic dysreflexia plan, skin, bladder, bowel, respiratory care, bone and cardiometabolic health, mood, and care team needs | finished | S |
| 2026-04-27 | Two-week review and physical medicine and rehabilitation (spinal cord injury medicine) consultation, with a bone density scan and kidney and bladder ultrasound | finished | S |
| 2026-06-22 | Ten-week review: pacer conditioning, skin, vitamin D, and seating | finished | S |
| 2026-08-24 | Four-month review: kidney function, skin, mood, and equipment | finished | S |
| 2026-10-26 | Six-month review: respiratory care, skin, bladder and kidney surveillance, vaccines, and plans for the winter | finished | S |
| 2026-09-14 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Autonomic dysreflexia: a written plan and wallet card (sit him up, loosen clothing, check the catheter and bladder, then the bowel and skin; check blood pressure every 2 to 5 minutes; nitroglycerin ointment only if systolic pressure stays at 150 mmHg or higher), his baseline blood pressure recorded, and training for every nurse | completed | GL-CSCM-AD-2021 | S |
| Physical medicine and rehabilitation (spinal cord injury medicine) consultation to review the pacer conditioning plan, the autonomic dysreflexia plan, bladder and bowel management, bone health, spasticity and pain, and seating and equipment | completed | GL-CSCM-RESP-2005, GL-CSCM-AD-2021 | S |
| Pressure injury prevention: skin checks morning and night by his nurses, tilt-in-space pressure relief every 30 minutes in the chair, turning every 2 hours in bed on a pressure-redistributing mattress, cushion and seating review, nutrition, and the Braden scale at each visit | completed | GL-CSCM-PU-2014 | S |
| Neurogenic bladder: catheter care with monthly changes and closed drainage, no treatment of bacteria in the urine without symptoms, kidney function by cystatin C, and kidney and bladder ultrasound yearly | completed | GL-CSCM-BLADDER-2006, GL-AUA-NLUTD-2021 | S |
| Neurogenic bowel: a daily morning program with a suppository and digital stimulation, senna at night, fiber and fluids, reviewed at each visit | completed | GL-CSCM-BOWEL-2021 | S |
| Respiratory care: tracheostomy care, suctioning, daily mechanical insufflation-exsufflation for secretion clearance, a pacer conditioning schedule with oxygen saturation checks, a backup ventilator, a spare tracheostomy tube, a generator and battery plan for power cuts, and registration with the power company and emergency services | completed | GL-CSCM-RESP-2005 | S |
| Bone health and cardiometabolic risk: calcium, 25-hydroxyvitamin D and PTH, DXA of the hip and knee regions, continued electrically stimulated cycling, careful transfers; lipids, A1c and blood pressure yearly | completed | GL-CSCM-BONE-2022, GL-CSCM-CMR-2018, GL-CMID-2026 | S |
| Mood, pain, spasticity and venous thromboembolism: PHQ-9 at intake and twice a year, pain score at reviews, stretching and range of motion for spasticity, and checking for leg swelling, with urgent assessment for a new swollen leg | completed | GL-CSCM-MH-2021, GL-CSCM-VTE-2016, GL-CSCM-PAIN | S |
| On the consultant's advice: vitamin D3 2000 units daily with a recheck in about eight weeks, seating pressure mapping with a cushion review, a weekly step-up of pacer time as tolerated, and a repeat DXA in two years | completed | GL-CSCM-BONE-2022, GL-CSCM-PU-2014, GL-CSCM-RESP-2005, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Lengthen time on the diaphragm pacer to at least three hours twice a day by six months, with stable oxygen saturation | 2026-10-26 | completed | Pacer three hours twice a day; saturation 97 to 98% on the pacer | S |
| No pressure injury: skin intact at every check through six months | 2026-10-26 | completed | Skin intact at every visit; Braden 11 to 12 | S |
| Written autonomic dysreflexia plan held by him and every nurse, with all nurses trained, by the two-week visit | 2026-04-27 | completed | Plan and wallet card in place; all regular nurses trained | S |
| 25-hydroxyvitamin D at least 30 ng/mL within three months | 2026-06-22 | completed | 34 ng/mL at ten weeks | S |
| No unplanned hospital admission through six months | 2026-10-26 | completed | No admission | S |